LNCaP (ATCC, CVCL_0395) and C4-2B (ATCC, CVCL_4784) cells were cultured in RPMI medium (Thermo Fisher) supplemented with 5% FBS. Medium was changed every 3 days and cells were incubated at 37 °C in 5% CO2. For treatments representing androgen-deprivation therapy, cells were cultured in RPMI medium supplemented with 5% charcoal -stripped serum (CSS). For AR-targeted therapies, cells were cultured in 5% or 10% FBS with AR antagonist enzalutamide (Enz, 10 μM). Cells were passaged at approximately 80% confluency by trypsinization. Cell lines were genotyped in March 2018 by Genomics Research Centre (Brisbane) and routinely tested for mycoplasma infection.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.